What Changed
Price Move History
- Daily moves over 5%
- 48 252 sessions, November 17, 2025 to November 17, 2026
- Largest daily move
- +18.6% close of May 5, 2026
- 1-year change
- +100.1% closing prices, November 17, 2025 to November 17, 2026
- 1-month change
- -12.9% closing prices, October 16, 2026 to November 17, 2026
Company Description
Fortrea Holdings Inc. (NASDAQ: FTRE) is a global contract research organization (CRO) and provider of clinical development solutions to the life sciences industry. The company is classified in the Professional, Scientific, and Technical Services sector and the Testing Laboratories industry. Fortrea works with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to support the development of therapies from early clinical stages through late-stage studies.
According to company disclosures, Fortrea delivers phase I–IV clinical trial management, clinical pharmacology and consulting services. Its offerings are aimed at helping customers run clinical trials and advance potential treatments for patients. Fortrea states that its solutions build on three decades of experience across more than 20 therapeutic areas, emphasizing scientific rigor, insights from clinical development, and access to an investigator site network.
Fortrea describes itself as a global provider, with a team working in about 100 countries. This geographic reach is intended to support customers that run multinational clinical studies and need consistent processes and oversight across regions. The company highlights its ability to partner with both emerging and large organizations across the life sciences value chain.
In addition to the operational aspects of clinical development, Fortrea’s public communications reference its role in the broader financial and corporate landscape. The company’s common stock is listed on The NASDAQ Stock Market LLC under the symbol FTRE, and it has also registered rights to purchase Series A preferred stock. Fortrea has reported quarterly financial results, issued guidance, and engaged in capital structure actions such as a tender offer for senior secured notes, as reflected in its press releases and Form 8-K filings.
Fortrea has also used equity-based inducement awards under a dedicated inducement award plan for new hires, as disclosed in its SEC filings. The company’s board and leadership changes, including director appointments and executive roles such as general counsel, are documented through current reports on Form 8-K, indicating ongoing corporate governance activity.
Fortrea’s origins as a clinical development business that became an independent, publicly traded company are noted in third-party descriptions. The company is described as having been formed after a spin-off of a clinical development business previously owned by another organization. This background provides context for its focus on late-stage clinical development and its positioning as a CRO serving a wide range of life sciences customers.
Business focus and services
Fortrea’s core business centers on providing clinical development solutions. Based on company descriptions, these solutions include:
- Phase I–IV clinical trial management for biopharmaceutical, biotechnology, medical device and diagnostic companies.
- Clinical pharmacology services, which support the study of how potential therapies behave in the body.
- Consulting services related to clinical development.
The company positions these services as contributing to healthcare innovation by helping customers accelerate the development of life-changing therapies for patients. Its experience across numerous therapeutic areas and its investigator site network are presented as key elements of its operating model.
Industry context
Within the Testing Laboratories industry and the broader Professional, Scientific, and Technical Services sector, Fortrea operates as a contract research organization focused on clinical development. CROs typically support life sciences companies by managing and executing clinical studies and related activities. Fortrea’s own statements emphasize its role in partnering with customers across different sizes and segments of the life sciences industry.
Geographic footprint
Fortrea reports that its team works in about 100 countries. This global footprint is intended to support clinical development programs that require access to diverse patient populations and investigator sites. The company’s headquarters city is identified in multiple news releases as Durham, North Carolina.
Regulatory and public company status
Fortrea files reports with the U.S. Securities and Exchange Commission (SEC) as a public company. Recent Form 8-K filings show that:
- Its common stock, with a par value of $0.001 per share, is registered and trades under the symbol FTRE on The NASDAQ Stock Market LLC.
- Rights to purchase Series A preferred stock are also registered on the same exchange.
- The company periodically reports results of operations and financial condition through press releases furnished as exhibits to Form 8-K.
- Corporate actions such as a debt tender offer for senior secured notes and amendments to an inducement award plan are disclosed via Form 8-K.
These filings provide insight into Fortrea’s financial reporting, capital structure management, and governance practices.
Company history
Third-party descriptions indicate that Fortrea was formed as an independent, publicly traded company after a spin-off of a clinical development business from another organization. That clinical development business had previously been acquired through a transaction involving Covance. This history underpins Fortrea’s emphasis on three decades of experience in clinical development and its focus on late-stage contract research activities.
Use cases for investors and observers
For investors and others researching FTRE stock, Fortrea represents exposure to a contract research organization that operates in the life sciences clinical development space. Public information highlights:
- Its role as a global provider of clinical development solutions.
- Its customer base across biopharmaceutical, biotechnology, medical device and diagnostic companies.
- Its presence in numerous therapeutic areas.
- Its public company status on NASDAQ and ongoing SEC reporting.
Fortrea’s press releases also discuss topics such as quarterly financial performance, guidance, cost-saving initiatives, debt tender offers, leadership appointments, and collaborations with other organizations in areas like cell and gene therapy development.
Stock Performance
Fortrea Holdings (FTRE) closed at $19.59 on November 17, 2026. Over the past 12 months, the price has gained 100.1%.
FTRE Metrics & Rankings
Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Fortrea Holdings has 10 recent news articles. Of the recent coverage, 7 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings, acquisition, conferences, earnings date. View all FTRE news →
SEC Filings
Fortrea Holdings has filed 10 recent SEC filings, including 3 Form 4, 3 Form 8-K, 2 Form 144, 1 Form 10-Q. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all FTRE SEC filings →
Insider Radar
Insider selling at Fortrea Holdings over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.
Financial Highlights
Fortrea Holdings generated $2.7B in revenue in FY2025, retaining a 18.5% gross margin, operating income reached -$872.6M (-32.0% operating margin), and net income was -$986.2M, reflecting a -36.2% net profit margin. Diluted earnings per share stood at -$10.81. The company generated $113.5M in operating cash flow. The current ratio was 0.98, measuring current assets divided by current liabilities.
Upcoming Events
Jefferies Fireside Chat
RSU first vesting
RSU vesting 1st installment
RSU vesting installment 1
First RSU vesting
RSU second vesting
RSU vesting 2nd installment
RSU vesting installment 2
Second RSU vesting
RSU final vesting
RSU vesting final installment
RSU vesting installment 3
Final RSU vesting
PSU performance vesting
Fortrea Holdings has 14 upcoming scheduled events. Investors can track these dates to stay informed about potential catalysts that may affect the FTRE stock price.
Short Interest History
Short interest in Fortrea Holdings (FTRE) currently stands at 8.6 million shares, up 11.7% from the previous reporting period, representing 9.0% of the float. Since November 2025, short interest has decreased by 13.5%.
Days to Cover History
Days to cover for Fortrea Holdings (FTRE) currently stands at 3.7 days, down 8.1% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 52.2%. Across the settlements charted above, it has ranged from 3.7 to 11.9 days.
FTRE Company Profile & Sector Positioning
Fortrea Holdings (FTRE) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing FTRE often look at related companies in the same sector, including Maravai LifeSciences Holdings, Inc. (MRVI), Recursion Pharmaceuticals, Inc. (RXRX), Agios Pharmaceuticals, Inc. (AGIO), Zymeworks Inc. (ZYME), and Trevi Therapeutics, Inc. (TRVI). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate FTRE's relative position within its industry.